Literature DB >> 2272826

[Serodiagnosis in dermatological diseases in Borrelia burgdorferi infections].

H Hofmann1, U Meyer-König.   

Abstract

185 patients with dermatological symptoms of Borrelia burgdorferi infection (erythema migrans, lymphadenosis cutis benigna, acrodermatitis chronica atrophicans) and morphea were examined for Borrelia burgdorferi antibodies; in addition, sera from 173 patients were tested for exclusion of Borrelia infection. Commercially available immunofluorescence tests and enzyme immunoassays supplied by four different companies were evaluated. To investigate the specificity of these assays, sera of 34 patients with syphilis in different stages and sera from 98 control persons were examined. None of the assays evaluated was suitable for the diagnosis of early infection (sensitivity 4-35%). However, they are more reliable for the diagnosis of late infection (sensitivity 56-100%). The variation in specificity between the different assays was 82-100%. Crossreactions with Borrelia burgdorferi antibodies occurred frequently in patients with syphilis (3-47%). The reliability of serological assays should be improved by antigen purification and combination of screening and confirmatory assays. After treatment the decline in IgG and IgM antibodies is very slow.

Entities:  

Mesh:

Year:  1990        PMID: 2272826

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  2 in total

1.  Sudeck's atrophy in Lyme borreliosis.

Authors:  H R Bruckbauer; V Preac Mursic; P Herzer; H Hofmann
Journal:  Infection       Date:  1997 Nov-Dec       Impact factor: 3.553

Review 2.  The diagnostic accuracy of serological tests for Lyme borreliosis in Europe: a systematic review and meta-analysis.

Authors:  M M G Leeflang; C W Ang; J Berkhout; H A Bijlmer; W Van Bortel; A H Brandenburg; N D Van Burgel; A P Van Dam; R B Dessau; V Fingerle; J W R Hovius; B Jaulhac; B Meijer; W Van Pelt; J F P Schellekens; R Spijker; F F Stelma; G Stanek; F Verduyn-Lunel; H Zeller; H Sprong
Journal:  BMC Infect Dis       Date:  2016-03-25       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.